As a woman, taking good care of yourself is essential factor in your life. Nowadays, there are a lot of dangers when it comes to your health that can threaten your own life. Cancer in the breast is one of the many forms of cancer that occurred mostly in women, but in some instances some men have also this kind of illness. No matter what old you are, you can still get a chance to have this kind of cancer. Even though it is more widespread in women that range in 40 years old or above, you must begin doing breast examinations as soon as possible. This is simply because you can really aid yourself to avoid cancer in the breast with early discovery. If you are unable to avoid it, you are going to be capable to have a better probability of eliminating of it the sooner that you do discover it.

The question is how to avoid getting breast cancer.

According to experts, they suggested that every woman to do breast cancer examinations every three years. This is after you attain the period your late 20′s and 30′s. Nevertheless, you need to remember that cancer in the breast is something that you are capable to notice within yourself. It is always fine to keep a close observance on your breasts. Every a couple of days, you must feel your breasts while you are taking a shower to examine for some sort of lumps. These lumps can be indications of this kind of cancer. The lumps will typically be firm and obvious.

In addition, when it comes to examination your own breasts, there are a couple of periods of the month that is the best period to examine for cancer in the breast. This is a better way to do early breast screening finding to aid you to avoid having this kind of cancer. Even though some individuals still believe that you must examine for breast cancer every a couple of days, you are actually only believe to examine it about once per month. Still, do bear in mind that checking it more than once every month is not bad at all.

Furthermore, the best period to examine your breast is the day after your menstrual period. This is the best moment to do self-examination because your breasts are expected to be less stinging and tender. If you are an individual that has irregular menstrual cycle, then you can examine your beast any period of the month. Do not worry since you will still acquire the same result. Remember that you have to try to perform self-examination when your breasts are not aching. This way you can perform a much better task to check it without distressing about your breasts being too painful to touch.

On the other hand, if you do not believe that checking your breasts with lumps are the best way to do for an early finding of getting breast cancer, you can always perform to have mammograms. This is an X-ray for your breasts that is capable to see the smallest tumors on your breast. As you know on how to avoid getting breast cancer, you will definitely be sure of that you will not getting this form of cancer later in life.

Women’s Health Initiative, a hug research funded by the federal, found out that people who consumed calcium medicine were associated with greater risk for strokes and heart attacks.

A study of information gathered from over 16,000 women who joined the research raised new questions with regard to the safety of calcium medicines, which several women consumed to keep their bone healthy and its connection to a possible risk of having strokes and heart attacks.

The Women’s Health Initiative astonished women and physicians in 2002 when it settled on that the danger of taking hormones for menopause women compensated the advantages. When the information from that research was initially studied, it found out that no increased for cardiovascular problems among women taking Vitamin D and calcium medicines.

However, most of these women who participated in the study were already taking calcium medicines on their own, which may have concealed any dangers. That is why Ian Reid and colleagues from University of Auckland restudied the information to take that into account.

The latest study of that information from 16,718 women, issued in the British medical journal called BMJ, found out that women who were not taking calcium medicines when the research began but started taking it when they joined the study project were at 13 to 22 percent increased risk.

The researchers found out that the jeopardy occurred in spite of whether the participants were taking calcium medicine with Vitamin D, or taking calcium medicine alone. They also studied information from 13 other researches that involved 29,000 participants overall, and found out increases in the risk of having strokes and developing heart failures among those who take calcium medicine.

In addition, the researchers think that there may be something about abruptly beginning calcium that increases the risk, maybe by causing hardening or calcification of the arteries. They added that calcium medicine may also make it more possible that blood clots will form.

Researchers said Monday that taking aspirin daily for five to ten years will reduce risk of death from cancer during that time by about ten percent.

The new review of studies led by Peter Rothwell of John Radcliffe Hospital in Oxford, England, was published online in the journal The Lancet Monday. Researchers found that after five years, cancer death rates decreased by 21 percent in patients who were assigned to take an aspirin a day.

The findings were taken from the analysis of 25,570 individuals participating in eight randomized studies. Researchers said that the findings are consistent with previous research, showing that aspirin averts colorectal cancer. They called the results as the first reliable evidence that aspirin prevents non-colorectal cancer in humans.

Mary Beth Terry, an associate professor at the Columbia Mailman School of Public Health in New York, said that the findings suggest that aspirin can reduce cancer risk of many different tumor sites. Moreover, the results were also convincing because it analyzes individual data from randomized clinical trials.

On the contrary, the American Cancer Society said that the findings are still premature at this point to put everyone on daily aspirin. Eric Jacobs, an official from cancer society, said that even low-dose aspirin can significantly increase the risk of serious gastrointestinal bleeding. He said that guidelines committees must carefully consider these new findings together with the existing evidence in order to decipher for whom the benefits of aspirin use are likely to outweigh the risks. Nonetheless, he said that the study is still a major contribution that long-term daily aspirin use may lower mortality from certain cancers in addition to colorectal cancer.

Researchers said that high levels of variability and inconsistencies are found on drug labels and dosages in 200 top-selling liquid medications.

A study published in the Journal of the American Medical Association this week show recent findings that most of the 200 top-selling cough, allergy, analgesic and gastrointestinal liquid medicines that are being sold over the counter have one or more inconsistencies with the labeled directions and accompanying measuring device.

According to the study, almost a quarter of these products lacked necessary markings on the devices. Almost ninety percent includes superfluous markings between the product’s label and the enclosed devices. The study was conducted for a year by the New York University School of Medicine and Bellevue Hospital Center. Researchers said that more than half of American children have been exposed to one or more medications given in a week and more than half of these are over-the-counter drugs.

Dr. John Allred, a pediatrician at Ogden Clinic, said that they are currently calculating on the standard volume that a child is required to drink. He said that pediatricians calculate the dosage based on the patient’s weight. However, a problem will arise once a parent tries to figure it out on her own, which is eventually putting her child’s health at risk.

Tim Drake, a pharmacist at McKay-Dee Hospital, said that this kind of inconsistencies come with a dropper for dosing that has markings for two of the doses, which are usually high and low dose. Moreover, several products have different concentration, so parents must be really prudent not to switch between products.

Drake suggested that is best to contact the doctors once a person get sick, especially if the patient is a child. In case of doubt, it is always wise to ask a pharmacist for dosing recommendations as well. He said that instead of using measuring cups, parents can use oral syringe because of its detailed measuring lines. Do not try to estimate the measurements on giving medications.

More teenagers have higher chances of getting a prescription for a controlled drug, and it has more likely to doubled in the span of 15 years, a U.S. study suggests.

In addition, in 2007, about one in every nine teens and a person in every six young adults, who are in their 20s, obtained prescriptions for controlled drugs that are likely to be abuse like, sedatives, stimulants and pain killers.

Moreover, Dr. Cindy Thomas of Brandeis University in Waltham, Massachusetts, said that the study may discover that there are more than one prescription drug that can be seen in a certain person’s medicine cabinet in their homes, and it might be more dangerous if they have children.

Meanwhile, Dr. Robert Fortuna from the University of Rochester in New York said that not all teens and young adults with with prescriptions will abuse it or give it to others. He further said that while there is an indication that more teenagers are abusing these prescriptions and that doctors should withdraw from giving these types of medications, still, there are no concrete basis for the study.

Fortuna meanwhile stated that the aim of the study is to strengthen young people’s knowledge on the importance of prescriptions to them and its different risks that may impose thereat to them. Also, he said that the study is directed for the importance of the prescriptions’ proper use.

In addition, doctors should discuss the matter with their patients in order to avoid any wrongful indications of the prescription drugs.

Medicines from Merck and GlaxoSmithKline cut the risks of prostate cancer in men, health regulators claimed.

However, scientists questioned the general benefit of these two medicines since the cancers that they prevent are typically not life-threatening. The Food and Drug Administration’s reviewers also criticized that both companies only considered a small amount of African-American men, who are at greater risk to have prostate cancer.

In addition, the FDA will hold a public conference on the said medicines Wednesday. GlaxoSmithKline that was based in the United Kingdom has asked the agency to endorse its medicine Avodart for a new usage against prostate cancer, after study demonstrated a 23 percent decline in substandard tumors in prostate cancer among men who took the medicine.

On the other hand, Merck, which is based in Whitehouse Station, New Jersey, attained same outcomes with its medicine Proscar and is inquiring the agency to endorse labeling about the benefits of the medicine in lessening the risks of prostate cancer.

Moreover, both medicines are already endorsed to cure inflated prostate. However, health regulators also said that only small proportion of patients concerned were African-Americans, who are at higher risk of the disease.

Only four percent of patients in Merck were African-Americans, while the trial of GlaxoSmithKline only enrolled two percent of African-American patients. Furthermore, the FDA said that the pertinence to African-American men is not recognized because of marked under-representation.

The review of the agency also lifts wider questions about the significance of avoiding substandard cancers. According to the FDA, almost 80 percent if of the cancers the medicines prevent are not insistent because the cancers develop so slowly, they are not measured a threat to older men with less than 20 years of life expectancy.

According to a recent study, Celebrex, a painkiller drug for arthritis, helped prevent skin cancer in patients with precancerous lesions.

The rates of skin cancer keep mounting in the United States despite the common cautions to prevent too much exposure to the sun and to use sunscreen. Celebrex is a non-steroidal anti-inflammatory drug (NSAID) and researchers have long considered its potential use as a treatment for skin cancer.

The study was issued in The Journal of the National Cancer Institute on Monday. Scientists designated 240 individuals with actinic keratosis, a condition that is frequently a sign to skin cancer, to get either 200 milligrams of Celebrex twice a day or a placebo.

In addition, the volunteers were analyzed for new skin lesions after three, six and nine months of treatment and again another two months after the end of their treatment. The two groups did not vary in the amount of precancerous lesions.

However, by the period of the last test, the volunteers that take Celebrex had 41 percent less non-melanoma skin cancers compared with the group who took placebo. Moreover, the Food and Drug Administration (FDA) closed the study early when reports came out that NSAIDs may boost the risk of strokes and heart attacks.

Furthermore, Dr. Craig A. Elmets, one of the authors of the study from the University of Alabama, Birmingham, said that the results of the research imply that inhibitors of cyclooxygenase may give an added benefit to sunscreen to prevent non-melanoma cancer.

Researchers added that any advantages of the treatments must be equal against the bad events related with this group of compounds.

On the other hand, Dr. Christine E. McLaren and Dr. Frank L. Meyskins, an editorial authors that go with the study and both from UC Irvine, said that future researches are required to know whether the drug may have a use for preventing non-melanoma skin cancer, as well as other kinds of cancer, while not increasing the risks of strokes and heart attack.

The Drug Enforcement Administration (DEA) banned the five chemicals used in herbal blends to produce synthetic marijuana.

The prohibiting of those chemical substances is a response to reports of suicide, overdoses and addiction. According to Barbara Carreno, spokesperson of DEA, manufacturers of fake pot blends like K2, Red X Dawn, Blaze and Spice labeled the blends as compound trying to cover the intentional use.

In addition, the government started its emergency action on Wednesday to prohibit those fake pots. They are sold via Internet and drug paraphernalia stores to a growing market of young adults and teens.

The DEA take action to the newest trendy drug craze by introducing 30 days procedure to put the chemicals in similar category of drug as cocaine and heroin. The agency also responded after receiving rising numbers of reports of hallucinations, apprehensions, dependency from poison law enforcement, hospitals and centers.

Moreover, it was the best move the agency can take to obtain the products off in the legal market. There were also signs that the makers were already stirring to reformulate those pots using chemicals not wrapped by the awaiting veto.

The fake pots, a smokeable leaves of a plant that were coated with chemicals, has been the focus of law enforcement and lawmakers across the country. No less than 15 states have acted to control or outlaw one or more of the chemicals, as have some Scandinavian and European countries.

Furthermore, the man who produced three of the chemicals as part of his study funded by the government for almost 20 years said that they are unsafe and anybody who uses them is brainless. On the other hand, John W. Huffman, a retired researcher of organic chemistry in Clemson University, stated that those chemicals seem to be somewhat lethal.

Food and Drug Administration (FDA) announced the recall of two prescription painkiller drugs in the market due to serious damage it may caused for the heart.

The agency released scientific evidence that the two drugs have its potential risk of damaging the heart and cause fatal heart arrhythmias even at its recommended doses, due to the drugs active ingredient, propoxyphene. Xanodyne Pharmaceuticals, drug manufacturer of Darvon and Darvocet, agreed with the FDA to withdraw its drugs in the market.

Drugs that contain propoxyphene have been restricted in Great Britain since 2005, and the European Medicine Agency recommended their gradual removal of the drugs from the European Union market in June 2009, after they have found various risks it may cause to a patient, such as fatal overdose risk.

The FDA called out all drug manufacturers of generic propoxyphene to stop making drugs with this kind of substance and to recall drugs with this kind of content in the market.

Doctors need to discontinue prescribing these kinds of drugs to their patients, and patients on the other hand who are taking this drug, need to speak with their doctors as soon as possible to know what will be their right decision, to understand whether they need to stop the medication.

Dr. John Jenkins, director of the Office of New Drugs at the Center for Drug Evaluation and Research (CDER) in FDA, said that the new heart data and information they have may significantly modify the risk-benefit profile of propoxyphene.

Moreover, he said that the ability of the drug to reduce pain is no longer sufficient to the severe risk of the drug to increase heart problems.

According to Dr. Gerald J. Dal Pan, CDER’s Office of Surveillance and Epidemiology director, that having a data for the first time regarding the result of propoxyphene even at its standard dose can be harmful to the patient’s heart.

The Food and Drug Administration (FDA) on Thursday rejected the approval of Vivus prescription diet drug Qnexa.

However, officials of Vivus, which developed the drug claims that there could still be hope for the drug to reach market eventually.

Furthermore, the advisory committee to the FDA voted against the authorization of the drug last July thus the Thursday denial did not came as a surprise.  On the other hand, the officials of the makers of the drug stated that the company was given the encouragement in an investor’s conference, called last Friday to satisfy the concerns of FDA.

In addition, Qnexa is a blend of two existing drugs phentermine and topiramate.

Moreover, Vivus was asked by FDA to provide for additional studies that would showcase if whether the drug could cause birth defects and quantify the risks of possible birth defects.  The group also asked the company to do research if the drug has something to do with the slight rise in the heart rate that will increase the risk of probable cardiovascular problems like heart attack and stroke.

Chief executive of Vivus, Mountain View, California, Leland Wilson stated that the company have plans to answer FDA’s queries and that there is no need for further studies since adequate data exists.

According to a data from a two-year study presented by Vivus there are 4,323 respondents taking the medication that showed no increased risk of cardiovascular events as compared with those taking placebo.  The data of the study also showed that there is a 10% average weight loss of the total body weight.

Also, Wilson of Qnexa stated that the FDA is just assuring that the drug be use for the right patients and that FDA knows that obesity is the leading cause of hypertension, Type2 diabetes, and many more.